8.28
-0.29(-3.38%)
Currency In USD
| Previous Close | 8.57 |
| Open | 8.47 |
| Day High | 8.47 |
| Day Low | 8 |
| 52-Week High | 20.9 |
| 52-Week Low | 6.29 |
| Volume | 1.13M |
| Average Volume | 233,898 |
| Market Cap | 370.85M |
| PE | -15.33 |
| EPS | -0.54 |
| Moving Average 50 Days | 12.52 |
| Moving Average 200 Days | 13.2 |
| Change | -0.29 |
If you invested $1000 in Y-mAbs Therapeutics, Inc. (YMAB) since IPO date, it would be worth $345 as of December 21, 2024 at a share price of $8.28. Whereas If you bought $1000 worth of Y-mAbs Therapeutics, Inc. (YMAB) shares 5 years ago, it would be worth $255.4 as of December 21, 2024 at a share price of $8.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Dec 07, 2024 5:00 PM GMT
NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
GlobeNewswire Inc.
Nov 27, 2024 12:35 PM GMT
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
GlobeNewswire Inc.
Nov 08, 2024 11:35 AM GMT
Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth q